β-Lactamases- The threat renews

Current Protein and Peptide Science

Volumn 10, Issue 5, 2009, Pages 397-400

  Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

lactamase; Aantibiotic resistance; Penicillin

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; METICILLIN; METRONIDAZOLE; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; STREPTOMYCIN; SULBACTAM; TAZOBACTAM; TETRACYCLINE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; ENZYME ACTIVE SITE; ESCHERICHIA COLI; HUMAN; HYDROLYSIS; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; PENICILLIN RESISTANCE; PNEUMONIA; REVIEW; SKIN INFECTION; URINARY TRACT INFECTION;

BACTERIAL INFECTIONS; BETA-LACTAMASES; BETA-LACTAMS; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, CHEMICAL; PENICILLINS; STAPHYLOCOCCUS AUREUS; WORLD HEALTH;

EID: 70349492143     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920309789351994     Document Type: Review

References (33)

1. Lietz, E.J., Truher, H., Kahn, D., Hokenson, M.J., Fink, A.L. Lysine-73 is involved in the acylation and deacylation of β-lactamase. Biochemistry, 2000, 39, 4971-4981.
2. Escobar, W.A., Miller, J., Fink, A.L. Effects of site-specific mutagenesis of tyrosine 105 in a class A β-lactamase. Biochem. J., 1994, 303, 555-558.
3. Abraham, E.P., Chain, E. An enzyme from bacteria able to destroy penicillin. Nature, 1940, 146, 837.
4. Barber, M., Rozwadowska-Dowzenko, M. Infection by penicillin-resistant staphylococci. Lancet, 1948, 2, 641-644.,
5. Chen, H.Y., Bonfiglio, G., Allen, M., Piper, D., Edwardson, T., McVey, D., Livermore D.M. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles. J. Antimicrob. Chemother., 1993, 32, 247-266.
6. Henwood, C.J., Livermore, D.M., Johnson, A.P., James, D., Warner, M., Gardiner, A. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid: the Linezolid Study Group. J. Antimicrob. Chemother., 2000, 46, 931-940.
7. Williams, R.E.O. Epidemic staphylococci. Lancet, 1959, 1, 190-195.
8. Reynolds, P.E., Brown, D.F.J. Penicillin-binding proteins of β-lactam resistant strains of Staphylococcus aureus effect of growth conditions. FEBS Lett., 1985, 192, 28-32.
9. Boucher, H.W., Corey, G.R. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis., 2008, 46 (Suppl 5), S344-S349.
10. Anderson, E.S., Datta, N. Resistance to penicillins and its transfer in Enterobacteriaceae. Lancet, 1965, 1, 407-409.
11. Matthew, M. Plasmid-mediated β-lactamases of Gram-negative bacteria: properties and distribution. J. Antimicrob. Chemother., 1979, 5, 349-358.
12. Neu, H.C. The new β-lactamase-stable cephalosporins. Ann. Intern. Med., 1982, 97, 408-419.
13. Pain, R., Virden, R. In β-Lactamases, Hamilton-Miller J.M.T., Smith, J.T.; Eds.; Academic Press: New York, 1979, pp. 141-180.
14. Cartwright, S.J., Fink, A.L. Isolation of a covalent intermediate in β-lactamase I catalysis. FEBS Lett., 1982, 137, 186-188.
15. Tan, A.K., Fink, A.L. Identification of the site of covalent attachment of nafcillin, a reversible suicide inhibitor of β-lactamase. Biochem. J., 1992, 281, 191-196.
16. Rizwi, I., Tan, A.K., Fink, A.L., Virden, R. Clavulanate inactivation of Staphylococcus aureus β-lactamase. Biochem. J., 1989, 258, 205-209.
17. Livermore, D.M. Clinical significance of β-lactamase induction and stable derepression in gram-negative rods. Eur. J. Clin. Microbiol., 1987, 6, 439-445.
18. Livermore, D.M., Yang, Y.J. -lactamase lability and inducer power of newer β-lactam antibiotics in relation to their activity against β-lactamase-inducibility mutants of Pseudomonas aeruginosa. J. Infect. Dis., 1987, 155, 775-782.
19. Chow, J.W., Fine, M.J., Shlaes, D.M., Quinn, J.P., Hooper, D.C., Johnson, M.P., Ramphal, R., Wagener, M.M., Miyashiro, D.K., Yu, V.L. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med., 1991, 115, 585-590.
20. Cosgrove, S.E., Kaye, K.S., Eliopoulous, G.M., Carmeli, Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med., 2002, 162, 185-190.
21. Philippon, A., Labia, R., Jacoby, G. Extended-spectrum β-lactamases. Antimicrob. Agents Chemother., 1989, 33, 1131-1136.
22. Ellerby, L.M., Escobar, W.A., Fink, A.L., Mitchinson, C., Wells, J.A. The role of lysine-234 in β-lactamase catalysis probed by site-directed mutagenesis. Biochemistry, 1990, 29, 5797-5806.
23. Escobar, W.A., Tan, A.K., Lewis, E.R., Fink, A.L. Site-directed mutagenesis of glutamate-166 in β-lactamase leads to a branched path mechanism. Biochemistry, 1994, 33, 7619-7626.
24. Osuna, J., Viadiu, H., Fink, A.L., Soberon, X. Substitution of Asp for Asn at position 132 in the active site of TEM β-lactamase. Activity toward different substrates and effects of neighboring residues. J. Biol. Chem., 1995, 270, 775-780.
25. Livermore, D.M., Canton, R., Gniadkowski, M., Nordmann, P., Rossolini, G.M., Arlet, G., Ayala, J., Coque, T.M., Kern-Zdanowicz, I., Luzzaro, F., Poirel, L., Woodford, N. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother., 2007, 59, 165-174.
26. Castanheira, M., Mendes, R.E., Rhomberg, P.R., Jones, R.N. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb. Drug Resist., 2008, 14, 211-216.
27. Schwaber, M.J., Carmeli, Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother., 2007, 60, 913-920.
28. Rodriguez-Bano, J., Navarro, M.D., Romero, L., Muniain, M.A., de Cueto, M., Rios, M.J., Hernandez, J.R., Pascual, A. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis., 2006, 43, 1407-1414.
29. Livermore, D.M. Determinants of the activity of β-lactamase inhibitor combinations. J. Antimicrob. Chemother., 1993, 31 (Suppl A), 9-21.
30. Paterson, D.L. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis., 2004, 38 (Suppl 4), S341-S345.
31. Queenan, A.M., Bush, K. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev., 2007, 20, 440-458.
32. Walsh, T.R. Clinically significant carbapenemases: an update. Curr. Opin. Infect. Dis., 2008, 21, 367-371.
33. Livermore, D.M. Can β-lactams be re-engineered to beat MRSA? Clin. Microbiol. Infect., 2006, 12 (Suppl 2), 11-16.